GLP-1, or Glucagon-like peptide-1 receptor agonists, are medications that treat type 2 diabetes and obesity
"In the brain, it's thought to reduce food intake by some element of appetite suppression," says Evan Nadler, MD, MBA , former co-director of the obesity program at Children's National Hospital and current adjunct associate professor at George Washington University
Your weight should be at or near your goal and holding steady, generally for at least six months
Preclinical studies in animal models have demonstrated that survodutide effectively activates both GLP-1R and GCGR, resulting in reduced body weight, slower gastric emptying, decreased energy intake, increased energy expenditure, and improved glucose tolerance [86]
Recent analyses presented at the National Lipid Associations 2025 Scientific Sessions highlighted cardiovascular, renal, and metabolic gains from GLP1s that appear partly independent of the amount of weight loss